[LIVE TRADE DAY] RAD - Down Over 12% After Missing Earnings

Good morning, Trader! Here are our top 4 trade ideas today. These setups look primed! Be the best prepared trader on the Street!  - [MyMD Pharmaceuticals, Inc. (MYMD)*](- As Inflation Rises and Economies Contract, Cases of Autoimmune Diseases Continue To Rise - RAD - Down Over 12% After Missing Earnings - FSLR - Evercore Upgrades to Outperform, Increases Target to $150 from $88 - PLTR - Extends Contract with U.S Army Worth Up to $229M *This is an Issuer-Paid Advertisement, See Disclosure Below  Sponsored By [MyMD Pharmaceuticals, Inc. (MYMD)*-]( As Inflation Rises and Economies Contract, Cases of Autoimmune Diseases Continue To Rise According to the Guardian, Internationally, it is now estimated that cases of autoimmune diseases are rising by between 3% and 9% a year. [MYMD’s]( primary drug is currently in Phase 2 clinical trials for treating autoimmune disease, and slowing the aging process.  The article states that “Most scientists believe environmental factors play a key role in this rise”.  “Human genetics hasn’t altered over the past few decades,” said Lee, who was previously based at Cambridge University. “So something must be changing in the outside world in a way that is increasing our predisposition to autoimmune disease.”  When panic sets into financial markets, it is always important to remember the fundamentals. Nothing for [MYMD]( has changed, it’s phase 2 trial is ongoing, and results could be a gamechanger for the company. The market for its potential treatment is growing every year.  After selling off to $2.13, [MYMD]( has found a strong bid and closed yesterday at $2.74. It’s now up almost 30% in a matter of days. This shows you how powerful reversal moves can be. The next logical target is a test of $3, above that, there is a gap to fill at $3.50. To the downside there is potential support at $2.50, below that a gap to fill at $2.22. [ MyMD Pharmaceuticals, Inc. (MYMD)*]( is a clinical-stage pharmaceutical company that develops drug products targeting aging, age-related, and autoimmune diseases. [Click Here To FInd Out More About the Company Working to Significantly Increase Lifespan](  *This is an Issuer-Paid Advertisement, See Disclosure Below  Jeff Bishop and Jason Bond Going LIVE at 7:30pm EST in the [Wall Street 360](room to chat Terminator Trades! Don’t Miss It! Jeff and Jason will discuss Terminator Trades and how they themselves use the powerful tools in Ben Sturgill’s service!  [Terminator Trades]( is Ben Sturgill’s most POWERFUL Trading Project! Here’s some of the trade ideas Ben’s students have been given access to:  [Here is your direct link to the 360 Wall Street Chat Room](  RAD - Down Over 12% After Missing Earnings Early this morning RAD reported a loss of $0.63 vs $0.55 expected, with sales $5.9B beating $5.77B estimates. They also lowered Full Year Guidance from $460-$500M to $450-$490M. The company also announced expected continued pressure on consumer spending and supply chain challenges according to Reuters. RAD is trading around $6.10 from a close of $7.03 yesterday. The next major areas of potential support are $5.75-$5.80 then $5.50 and below that $5. To the upside potential resistance is at $6.40/$6.50 and then a gap to fill at $7.03. Don’t miss our expert traders in the[360 Wall Street Chat Room]( as they alert their best trade ideas in real time!  FSLR- Evercore Upgrades to Outperform Increases Target to $150 from $88 FSLR also announced this morning that it had secured a multi-year agreement with 5N Plus for the supply of specialty semiconductors used in its solar panels.  FSLR closed strong yesterday with the overall market and is gapping higher this morning near the top of the range of this consolidation. There is a major resistance level at $140 which is also 52-week highs for the stock. Above that, targets are $150 then $160 in the short-term. A failure at $140 I’d expect to see $130 tested again. However, if FSLR does not break out here, I would think the stock could march much lower with $120 in play. [Here is your direct link to the 360 Wall Street Chat Room](  PLTR- Extends Contract With U.S Army Worth Up to $229M PLTR is extremely oversold from the highs it made last year. While the rest of the market has been getting the Kibosh, PLTR has been consolidating nicely for over a month now and is coming out of a nice base. While this is just a contract renewal and not a big change in fundamentals, it is still positive news for the company.  $8-$8.10 is a major resistance level that has been holding PLTR back. Above that I would expect a quick move to $8.43 and then the next target would be $9. A failure at $8 would put $7.50 in play and then a retest of the recent lows around $7.20. [Here is your direct link to the 360 Wall Street Chat Room](  To Your Success! 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360.com](  © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions  *THIS IS AN ISSUER-PAID ADVERTISEMENT, SEE DISCLOSURE BELOW*ISSUER-PAID ADVERTISEMENT. MyMD, Inc. (“MYMD” or the “Company”) HAS PAID ORWILL PAY SHERWOOD VENTURES, LLC (“Sherwood”) TWENTY-THOUSAND DOLLARS USD PER MONTH FOR THREE MONTHS (THE “INITIAL TERM”) IN CASH, SHARES OF RESTRICTED COMMON STOCK WITH A VALUE OF ONE-HUNDRED-FIFTY THOUSAND DOLLARS, AND WARRANTS VALUED AT ISSUANCE OF SEVENTY-FIVE THOUSAND DOLLARS FOR MARKETING SERVICES INCLUDING COMMUNICATING TO THE PUBLIC ABOUT THE COMPANY THROUGH SHERWOOD’S AFFILIATE RAGINGBULL.COM, LLC (“RAGING BULL”), AMONG OTHERS. THIS ADVERTISEMENT IS PART OF THOSE ISSUER-PAID MARKETING SERVICES. FOR DETAILED COMPENSATION AND MORE INFORMATION, PLEASE SEE THE FULL DISCLOSURE LOCATED AT HTTPS://BOARDROOMINVESTING.COM/MYMD-DISCLAIMER. DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of [RagingBull.com](, LLC are paid in whole or in part by commission based on their sales of Services to subscribers. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [Manage your email subscriptions.](